LTRN earnings analysis
What we found in LTRN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt contains controls-and-procedures and other-information disclosures but does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment results. Accordingly, revenue, margins, EPS, cash flow, balance-sheet trends, and quantitative guidance cannot be assessed from the supplied filing text. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the quarter.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls deemed effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
- No material control changes
- The company reported no changes in internal control over financial reporting during the three months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, those controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Internal-control limitations
- The company states that its controls provide only reasonable, not absolute, assurance; errors or fraud may remain undetected because of limitations including mistake, collusion, management override, and resource constraints.
- Risk-factor disclosure is limited
- As a Smaller Reporting Company, Lantern is exempt from Item 1A risk-factor disclosure, limiting the filing's update on material business, liquidity, and financing risks.
What they said about what is next.
No quantitative revenue or EPS outlook is disclosed in the provided 10-Q text. The filing does not provide a prior-outlook comparison.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- Lantern Pharma reported Q1 results for FY 2026 with an adjusted EPS loss of -$0.36, slightly better than the estimated loss of -$0.45. The company continues to face challenges with zero revenue generation during the…
- 10-K · April 30, 2026
- Lantern Pharma's 10-K for fiscal 2025 reveals persistent financial challenges but a focus on AI-driven precision therapeutics. Revenue generation remains a critical gap, while leadership changes and ongoing FDA…
- 10-K · March 30, 2026
- Lantern Pharma positions itself as an AI-driven precision oncology company centered on its RADR® platform (now >200 billion data points and 200+ ML algorithms) to 'rescue' historical small molecules and develop de-novo…
- 10-K · March 27, 2025
- Lantern Pharma positions itself as an AI-driven precision oncology company leveraging its RADR® platform ("more than 100 billion data points") to 'rescue' prior drug candidates and advance de-novo programs; it currently…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LTRN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever